Promis Neurosciences INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Johanne Kaplan, Chief Development Officer of ProMIS Neurosciences Inc., purchased 2,280 shares of common stock on August 5, 2026 for $13.30 per share.
NASDAQ
Director William Wyman was granted 16,500 stock options in ProMIS Neurosciences Inc. as part of board compensation.
NASDAQ
Director Eugene Williams was granted options to purchase 16,500 common shares of ProMIS Neurosciences Inc.
NASDAQ
CEO Neil Warma was granted 160,000 stock options in ProMIS Neurosciences with an exercise price of $10.77.
NASDAQ
Director Madge K. Shafmaster was granted 16,500 stock options in ProMIS Neurosciences Inc. as part of board compensation.
NASDAQ
Chief Scientific Officer Neil Cashman was granted 50,000 stock options in ProMIS Neurosciences, vesting over four years.
NASDAQ
Principal Accounting Officer Max A. Milbury was granted 18,167 stock options in ProMIS Neurosciences Inc.
NASDAQ
Chief Development Officer Johanne Kaplan was granted 50,000 stock options in ProMIS Neurosciences.
NASDAQ
Director Paul Alex Slanix was granted stock options for 16,500 common shares of ProMIS Neurosciences Inc.
NASDAQ
Director Patrick D. Kirwin acquired 4,000 shares of ProMIS Neurosciences Inc. at 11.33 dollars per share, signaling internal confidence.
NASDAQ
A director of ProMIS Neurosciences Inc. has purchased 2,000 common shares, increasing their direct beneficial ownership.
NASDAQ
ProMIS Neurosciences Inc. Director Eugene Williams acquired 4,000 common shares totaling $92,420 over three days in early March 2026.
NASDAQ
ProMIS Neurosciences' Chief Development Officer, Johanne Kaplan, acquired 1,629 common shares at $15.35 per share.
NASDAQ
ProMIS Neurosciences' Chief Scientific Officer and Director, Neil Cashman, acquired 4,122 common shares and an equal number of warrants.
NASDAQ
ProMIS Neurosciences' Chief Development Officer, Johanne Kaplan, acquired 2,060 common shares and an equal number of warrants as part of a securities purchase agreement.
NASDAQ
ProMIS Neurosciences Inc. CEO Neil K Warma acquired 6,183 common shares and an equal number of warrants in a transaction dated February 3, 2026.
NASDAQ
ProMIS Neurosciences' Principal Accounting Officer, Max A. Milbury, acquired 6,595 common shares and warrants in a recent transaction.
NASDAQ
ProMIS Neurosciences Director Patrick D. Kirwin acquired 3,050 common shares and warrants in a private placement, increasing his beneficial ownership.
NASDAQ
ABG Management and affiliated entities, including director Fan Yu, acquired over 700,000 common shares and warrants in ProMIS Neurosciences Inc. for an aggregate of $8.5 million.
NASDAQ
A director of ProMIS Neurosciences Inc. was granted 40,000 stock options with a $0.45 exercise price, vesting over time.
NASDAQ
ProMIS Neurosciences' Principal Accounting Officer, Max A. Milbury, acquired 30,392 common shares at $0.4912 per share, increasing his direct beneficial ownership to 45,389 shares.
NASDAQ
A 10% owner and director of ProMIS Neurosciences Inc. has filed a Form 4 detailing planned future warrant exercises and new warrant acquisition under a 10b5-1 plan.
NASDAQ
ProMIS Neurosciences Inc.'s Chief Medical Officer, Larry Altstiel, was granted 165,000 stock options with an exercise price of $0.45, vesting over time.
NASDAQ
ProMIS Neurosciences Inc. CEO Neil Warma was granted 600,000 stock options with an exercise price of $0.45, vesting over time.
NASDAQ
ProMIS Neurosciences Inc. granted 60,000 stock options to Principal Accounting Officer Max A. Milbury with an exercise price of $0.45, vesting over time.
NASDAQ
ProMIS Neurosciences' Chief Scientific Officer, Neil Cashman, was granted 165,000 stock options with an exercise price of $0.45, vesting over time.
NASDAQ
ProMIS Neurosciences' Chief Development Officer, Johanne Kaplan, was granted 165,000 stock options with an exercise price of $0.45.
NASDAQ
A ProMIS Neurosciences Inc. director and 10% owner significantly increased beneficial ownership through warrant exercises and new warrant acquisition.
NASDAQ
An amended SEC filing corrects the exercise price for Title 19 Promis's warrant transactions with ProMIS Neurosciences Inc. to $0.83518 per share.
NASDAQ
An amended SEC filing reveals a correction to the exercise price of warrants by a significant holder, impacting capital raised and ownership stake.